EU drug agency recommends approving COVID-19 treatment

covid-19
Credit: Unsplash/CC0 Public Domain

The European Union's drugs agency on Monday recommended approving the use of an anti-inflammatory medicine to treat adults hospitalized with severe COVID-19.

The European Medicines Agency decision, which has to be confirmed by the E.U.'s executive commission, extends the use of the drug RoActemra, made by Swiss pharmaceuticals giant Roche, that is currently used to treat forms of arthritis.

The Amsterdam-based EMA said it can now be used on adult COVID-19 patients who are being treated with corticosteroids and require supplemental oxygen or mechanical ventilation. The drug, given through an IV, tamps down a protein called interleukin-6 that's often found in excess in COVID-19 patients.

The agency said a study of 4,116 hospitalized adults with severe COVID-19 showed that treatment with RoActemra in addition to standard treatment reduced the risk of death when compared with alone.


Explore further

EU drug agency starts evaluating new COVID-19 treatment

© 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

Citation: EU drug agency recommends approving COVID-19 treatment (2021, December 6) retrieved 24 January 2022 from https://medicalxpress.com/news/2021-12-eu-drug-agency-covid-treatment.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
29 shares

Feedback to editors